MiNK Therapeutics reported a $4.2 million net loss for the fiscal second quarter of 2025, announcing a $13 million equity raise after quarter-end. Key milestones included a complete remission case in metastatic testicular cancer and reduced operating cash burn. Strategic partnerships are being pursued to maximize value and extend cash runway through mid-2026. Landmark clinical outcomes were achieved with AGENT-797 in refractory cancer indications, supporting potential regulatory and commercial opportunities. Externally funded trials for GVHD and ARDS reduce financial risk for MiNK, with top-line data expected by the end of 2025. No formal revenue guidance was provided.

Read more at Nasdaq: MiNK Therapeutics Extends Cash Runway